1. Home
  2. HPP vs ATXS Comparison

HPP vs ATXS Comparison

Compare HPP & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hudson Pacific Properties Inc.

HPP

Hudson Pacific Properties Inc.

HOLD

Current Price

$12.04

Market Cap

648.9M

Sector

Finance

ML Signal

HOLD

Logo Astria Therapeutics Inc.

ATXS

Astria Therapeutics Inc.

HOLD

Current Price

$12.93

Market Cap

722.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPP
ATXS
Founded
1997
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
648.9M
722.1M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
HPP
ATXS
Price
$12.04
$12.93
Analyst Decision
Hold
Hold
Analyst Count
12
6
Target Price
$19.39
$24.33
AVG Volume (30 Days)
1.2M
1.3M
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$781,676,000.00
$706,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.69
$3.56
52 Week High
$24.01
$13.29

Technical Indicators

Market Signals
Indicator
HPP
ATXS
Relative Strength Index (RSI) 75.18 65.69
Support Level $12.91 $12.70
Resistance Level $14.21 $13.29
Average True Range (ATR) 0.59 0.22
MACD 0.42 -0.05
Stochastic Oscillator 77.86 67.84

Price Performance

Historical Comparison
HPP
ATXS

About HPP Hudson Pacific Properties Inc.

Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Share on Social Networks: